224 related articles for article (PubMed ID: 20099974)
1. Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer.
Tajtakova M; Pidanicova A; Valansky L; Lachvac L; Nagy V; Sivonova M; Dobrota D; Kliment J; Petrovicova J
Neoplasma; 2010; 57(2):118-22. PubMed ID: 20099974
[TBL] [Abstract][Full Text] [Related]
2. Evaluating serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis.
Rainato G; Fabricio AS; Zancan M; Peloso L; Dittadi R; Barichello M; Fandella A; Scattoni V; Gion M
Int J Biol Markers; 2016 Jul; 31(3):e317-23. PubMed ID: 26954072
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
4. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
[TBL] [Abstract][Full Text] [Related]
5. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
Safarinejad MR; Shafiei N; Safarinejad S
Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.
Cao Y; Lindström S; Schumacher F; Stevens VL; Albanes D; Berndt S; Boeing H; Bueno-de-Mesquita HB; Canzian F; Chamosa S; Chanock SJ; Diver WR; Gapstur SM; Gaziano JM; Giovannucci EL; Haiman CA; Henderson B; Johansson M; Le Marchand L; Palli D; Rosner B; Siddiq A; Stampfer M; Stram DO; Tamimi R; Travis RC; Trichopoulos D; Willett WC; Yeager M; Kraft P; Hsing AW; Pollak M; Lin X; Ma J
J Natl Cancer Inst; 2014 Jun; 106(6):dju085. PubMed ID: 24824313
[TBL] [Abstract][Full Text] [Related]
7. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population.
Sivoňová MK; Dobrota D; Dušenka R; Waczulíková I; Slezák P; Matáková T; Mahmoodová S; Mištuna D; Kliment J
Mol Biol Rep; 2012 Aug; 39(8):7871-80. PubMed ID: 22528335
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.
Schumacher FR; Cheng I; Freedman ML; Mucci L; Allen NE; Pollak MN; Hayes RB; Stram DO; Canzian F; Henderson BE; Hunter DJ; Virtamo J; Manjer J; Gaziano JM; Kolonel LN; Tjønneland A; Albanes D; Calle EE; Giovannucci E; Crawford ED; Haiman CA; Kraft P; Willett WC; Thun MJ; Le Marchand L; Kaaks R; Feigelson HS; Bueno-de-Mesquita HB; Palli D; Riboli E; Lund E; Amiano P; Andriole G; Dunning AM; Trichopoulos D; Stampfer MJ; Key TJ; Ma J
Hum Mol Genet; 2010 Aug; 19(15):3089-101. PubMed ID: 20484221
[TBL] [Abstract][Full Text] [Related]
10. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
Antognelli C; Mearini L; Talesa VN; Giannantoni A; Mearini E
Prostate; 2005 May; 63(3):240-51. PubMed ID: 15538743
[TBL] [Abstract][Full Text] [Related]
11. Genotypes and haplotypes in the insulin-like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density.
Biong M; Gram IT; Brill I; Johansen F; Solvang HK; Alnaes GI; Fagerheim T; Bremnes Y; Chanock SJ; Burdett L; Yeager M; Ursin G; Kristensen VN
BMC Med Genomics; 2010 Mar; 3():9. PubMed ID: 20302654
[TBL] [Abstract][Full Text] [Related]
12. Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses.
Murphy N; Carreras-Torres R; Song M; Chan AT; Martin RM; Papadimitriou N; Dimou N; Tsilidis KK; Banbury B; Bradbury KE; Besevic J; Rinaldi S; Riboli E; Cross AJ; Travis RC; Agnoli C; Albanes D; Berndt SI; Bézieau S; Bishop DT; Brenner H; Buchanan DD; Onland-Moret NC; Burnett-Hartman A; Campbell PT; Casey G; Castellví-Bel S; Chang-Claude J; Chirlaque MD; de la Chapelle A; English D; Figueiredo JC; Gallinger SJ; Giles GG; Gruber SB; Gsur A; Hampe J; Hampel H; Harrison TA; Hoffmeister M; Hsu L; Huang WY; Huyghe JR; Jenkins MA; Keku TO; Kühn T; Kweon SS; Le Marchand L; Li CI; Li L; Lindblom A; Martín V; Milne RL; Moreno V; Newcomb PA; Offit K; Ogino S; Ose J; Perduca V; Phipps AI; Platz EA; Potter JD; Qu C; Rennert G; Sakoda LC; Schafmayer C; Schoen RE; Slattery ML; Tangen CM; Ulrich CM; van Duijnhoven FJB; Van Guelpen B; Visvanathan K; Vodicka P; Vodickova L; Vymetalkova V; Wang H; White E; Wolk A; Woods MO; Wu AH; Zheng W; Peters U; Gunter MJ
Gastroenterology; 2020 Apr; 158(5):1300-1312.e20. PubMed ID: 31884074
[TBL] [Abstract][Full Text] [Related]
13. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies.
Chen W; Wang S; Tian T; Bai J; Hu Z; Xu Y; Dong J; Chen F; Wang X; Shen H
Eur J Hum Genet; 2009 Dec; 17(12):1668-75. PubMed ID: 19491931
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study.
Adachi Y; Nojima M; Mori M; Matsunaga Y; Akutsu N; Sasaki S; Endo T; Kurozawa Y; Wakai K; Tamakoshi A;
Tumour Biol; 2016 Nov; 37(11):15125-15132. PubMed ID: 27662841
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Sarma AV; Dunn RL; Lange LA; Ray A; Wang Y; Lange EM; Cooney KA
Prostate; 2008 Feb; 68(3):296-305. PubMed ID: 18163429
[TBL] [Abstract][Full Text] [Related]
16. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer.
Al-Zahrani A; Sandhu MS; Luben RN; Thompson D; Baynes C; Pooley KA; Luccarini C; Munday H; Perkins B; Smith P; Pharoah PD; Wareham NJ; Easton DF; Ponder BA; Dunning AM
Hum Mol Genet; 2006 Jan; 15(1):1-10. PubMed ID: 16306136
[TBL] [Abstract][Full Text] [Related]
17. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
[TBL] [Abstract][Full Text] [Related]
18. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.
Gu F; Schumacher FR; Canzian F; Allen NE; Albanes D; Berg CD; Berndt SI; Boeing H; Bueno-de-Mesquita HB; Buring JE; Chabbert-Buffet N; Chanock SJ; Clavel-Chapelon F; Dumeaux V; Gaziano JM; Giovannucci EL; Haiman CA; Hankinson SE; Hayes RB; Henderson BE; Hunter DJ; Hoover RN; Johansson M; Key TJ; Khaw KT; Kolonel LN; Lagiou P; Lee IM; LeMarchand L; Lund E; Ma J; Onland-Moret NC; Overvad K; Rodriguez L; Sacerdote C; Sánchez MJ; Stampfer MJ; Stattin P; Stram DO; Thomas G; Thun MJ; Tjønneland A; Trichopoulos D; Tumino R; Virtamo J; Weinstein SJ; Willett WC; Yeager M; Zhang SM; Kaaks R; Riboli E; Ziegler RG; Kraft P
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2877-87. PubMed ID: 20810604
[TBL] [Abstract][Full Text] [Related]
19. Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features.
Samzadeh M; Hasanzad M; Jamaldini SH; Haghdoost AA; Afshari M; Ziaee SA
Urol J; 2012; 9(4):691-9. PubMed ID: 23235975
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
